EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study

Background: RECOVER is a multicentre post-approval study of ETI in pwCF in Ireland and the UK. The CFAbd-Score is the first validated CF-specific Patient Reported Outcome Measure (PROM) focusing on GI-symptoms. The CFAbd-Score comprises 28 items in 5 domains. In a preliminary study of 107 German and British people with CF (pwCF), we found that CFAbd-Scores markedly improve during 24 weeks of elexacaftor-tezacaftor-ivacaftor (ETI). 1 Mainz JG et al. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. Front Pharmacol. 2022 Jun; Crossref PubMed Scopus (11) Google Scholar